Edwards Lifesciences Corporation (NYSE:EW) Stock Has Consensus Price Target of $100.27

Key Points

• Analysts remain broadly positive: Edwards Lifesciences has a “Moderate Buy” consensus from 22 analysts, with an average 12-month price target of $100.27 versus a share price of $88.19.
• Latest quarterly results exceeded expectations: The company reported $0.78 in adjusted EPS and $1.74 billion in revenue, beating estimates and increasing revenue 13.6% year over year. Analysts expect approximately $3.00 in EPS for the current year.
• Institutional ownership is substantial, while insiders have sold shares: Institutional investors and hedge funds own 79.46% of the stock, while insiders sold 5,045 shares worth about $451,596 over the past three months.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-two research firms that are covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $100.27.

A number of research firms have recently issued reports on EW. JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Friday, July 24th. UBS Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research report on Thursday, October 8th. TD Cowen reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Citigroup reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Monday, October 5th. Finally, Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th.

Edwards Lifesciences Trading Up 1.1%

Shares of EW opened at $88.19 on Wednesday. The business's 50-day moving average price is $88.24 and its 200 day moving average price is $86.48. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $50.78 billion, a P/E ratio of 50.69, a P/E/G ratio of 2.29 and a beta of 0.87. Edwards Lifesciences has a 1-year low of $74.66 and a 1-year high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. The business's quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts expect that Edwards Lifesciences will post 3.00 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Annette Brüls sold 2,644 shares of the firm's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Andrew M. Dahl sold 544 shares of the firm's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 5,045 shares of company stock valued at $451,596 over the last three months. 0.31% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences during the first quarter worth about $25,000. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 1st quarter valued at $26,000. Pin Oak Investment Advisors Inc. acquired a new stake in Edwards Lifesciences during the 2nd quarter valued at $26,000. GK Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at $26,000. Finally, TrinityBridge Ltd bought a new position in Edwards Lifesciences in the 2nd quarter valued at $27,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart's valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.